ClinicalTrials.gg
Not yet recruitingNCT07939958Updated Nov 16, 2026

Effects of Cervical Joint Mobilization on Blood Flow, Hypersensitivity to Pressure and Neck Motions

An interventional study of Cervical Joint Mobilization in Neck Pain Musculoskeletal and Neck Pain, sponsored by Sharon Wang-Price. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Sharon Wang-Price · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to assess the immediate effects of cervical joint mobilization on patients experiencing neck-shoulder pain.

The main research questions are: (1) Does the joint mobilization intervention acutely change blood flow in the neck/shoulder area? (2) Does the joint mobilization intervention acutely increase pressure pain thresholds (PPTs)? (3) Does the joint mobilization intervention acutely increase cervical range of motion (ROM)? (4) Does the joint mobilization intervention acutely decrease the number of tender and hypertonic points?

This study utilizes a single-session, pre- and post-intervention design with no comparison group. Participants will attend one on-site visit (1.25 hours) for screening and intervention. First, each eligible participant will complete an intake form for demographics and three questionnaires: the Brief Pain Index (BPI), Neck Disability Index (NDI), and Central Sensitization Inventory (CSI).

Following the questionnaires, participants will undergo baseline assessments for their tender and hypertonic points, cervical ROMs, PPTs, and blood flow parameter. After the baseline assessments, each participant will receive a lateral glide oscillatory joint mobilization technique to the C4-C5 level for five minutes. Immediately following the intervention, all four outcome measures, including tender points, cervical ROM, PPTs and blood flow parameters will be re-assessed.

Read the detailed description

All participants are required to attend one on-site visit (\~ 1.25 hours). The procedures of this research study are described as follows:

  1. Administration of the Consent Form, Intake Form and Questionnaires At the beginning of the on-site visit, one investigator will describe the study purpose/procedures as well as the risks/benefits associated with this study to each participant. Once the participant agrees to participate in this study, the participant will be asked to sign the written consent form. Next, the participant will complete an intake form for their demographic information and the history of their neck-shoulder pain. Each participant also will complete 3 questionnaires: (1) Brief Pain Index (BPI), (2) Neck Disability Index (NDI) and (3) Central Sensitization Inventory (CSI). These 3 questionnaires will provide information of each participant's neck-shoulder pain, function level and degree of central sensitization/segmental facilitation.

    The BPI is a 9-item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The NDI is a self-report questionnaire used to determine how neck pain affects a patient's daily life and to assess the self-rated disability of patients with neck pain. The CSI consists of two parts: Part A is a 25-item self-report questionnaire designed to identify patients who have symptoms that may be related to central sensitization. Part B asks patients whether they have been diagnosed with 10 central sensitization syndromes, such as fibromyalgia, whiplash and migraine.

  2. Palpation Assessment for Presence of Hypertonicity and Tenderness During this palpation assessment, the participants will sit on a chair with back support. The participant will be instructed to keep their neck in a neutral position and their arms on a pillow placed on top of their thighs. The investigator will palpate for increased muscle tone and tender points along the participant's neck-shoulder (shawl) area further confirm the eligibility of the participant. At the same time, the investigator will collect one outcome measure by determining whether the following 4 sites are tender: (1) upper cervical segments (C1-C2), (2) C4-5 segment, (3) levator scapulae near the insertion, and (4) the middle of supraspinatus/upper trapezius muscles. A skin marker will be used to mark these 3 sites so that the investigator will assess the same locations during the re-assessments.
  3. Pre-intervention Assessments The following our outcome measures will be assessed while the participants are in seated position in the following order: (1) the number of tender and hypertonic points on the 4 sites as described above, (2) cervical range of motions (ROMs), (3) pressure pain thresholds (PPTs), and (4) blood flow parameter tested. In addition, there will be two pre-intervention assessment of blood flow parameter 5 minutes apart to establish test re-test reliability of assessments of blood flow parameters.
  4. Joint Mobilization Intervention After the 2nd assessments blood flow parameters, the participant will be asked to remain seated with their arms relaxed next to the trunk for joint mobilization. The treating investigator will apply joint mobilization to the cervical spine at the C4-5 level, using a lateral glide oscillatory technique, approximately 1 to 2 times per second for 5 minutes.
  5. Post-intervention assessment The 4 outcome measures will be assessed in the following order: (1) blood flow parameters e, (2) PPTs, (3) the number of tender points, and then (4) cervical ROMs tested in the seated position.
02

Conditions studied

  • Neck Pain Musculoskeletal
  • Neck Pain

Browse trials for

Keywords

  • cervical spine
  • manual therapy
  • levator scapulae muscle
  • pressure pain threshold
  • joint mobility
03

In context

Neck Pain

1,363 studies on the registry are indexed under Neck Pain; 300 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 1,117 interventional studies indexed under Neck Pain.

Browse Neck Pain studies →

Lead sponsor

Sharon Wang-Price is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults 18-65 years of age,
  • having neck-shoulder (over upper trapezius area) pain with an average pain ≥ 2/10 on the Numeric Pain Rating scale (0-10, 0 = no pain, 10 = unbearable pain)
  • having tenderness to palpation or increased muscle tone along the levator scapulae muscle.

Exclusion criteria

Exclusion Criteria:

  • Active systemic arthritis (e.g., rheumatoid arthritis, psoriatic arthritis)
  • Traumatic brain injury
  • Stroke
  • Seizures/epilepsy
  • Neurological disease (e.g., multiple sclerosis, muscular dystrophy, Parkinson's, spinal cord compression)
  • Fracture of cervical spine
  • Circulation/vascular problems (e.g., Raynaud's)
  • Cancer
  • Uncontrolled diabetes/high blood sugar
  • Currently pregnant
  • Previous neck surgery
  • Taking an anticoagulant (blood thinner)
  • Allergic to ultrasound gel
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cervical joint mobilization

    C4-5 non-thrust, oscillatory joint mobilization

    Procedure: Cervical Joint Mobilization

Interventions

  • ProcedureCervical Joint Mobilization

    C4-5 non-thrust, oscillatory joint mobilization

06

What researchers measure

Primary outcomes

  1. Blood flow - Peak Systolic Velocity

    Peak systolic velocity (PSV) will be used to determine the status of blood flow. A color Doppler ultrasonographic scanner (Sonosite PX, FUJIFILM Sonosite, Inc., Bothell, WA) and a linear transducer (6 cm, 19-5 MHz) will be used to determine PSV of the transverse cervical artery. The spectral Doppler waveforms will be automatically generated by the US scanner, displaying the velocities of blood flow in the dorsal scapular artery throughout the cardiac cycle. Three US images will be taken and the average of the three trials will be used for data analysis.

    Time frame: On the same day, this outcome measure will be collected twice: (1) Baseline, pre-intervention (2) Immediately after the intervention

  2. Pressure pain threshold

    Pressure pain threshold (PPT) of the levator scapula muscle will be determined handheld computerized pressure algometer (Medoc Ltd, Ramat Yishai, Israel). The testing site will be near the insertion of the levator scapula (i.e., superomedial border of the scapula). The algometer consists of a 1-cm squared round tip that will be pressed vertically over the testing site. The participant will be instructed to hold the response unit in the non-testing hand and press the button once the sensation of pressure changes to a sensation of pain. A total of 4 trials will be performed, and the average of the last 3 trials will be used for data analysis.

    Time frame: On the same day, this outcome measure will be collected twice: (1) Baseline, pre-intervention (2) immediately after the intervention

  3. Cervical motions

    Six cervical range of motion of flexion, extension, left and right rotations, and left and right side-flexions will be assessed using a CROM device (Fabrication Enterprises Inc., White Plains, NY). Each participant will perform each of six motions twice and the average of the two trials will be used for data analysis.

    Time frame: On the same day, this outcome measure will be collected twice: (1) Baseline, pre-intervention (2) Immediately after the intervention

Secondary outcomes

  1. Number of tender points

    Four sites will be assessed for tenderness and hypertonicity, including (1) upper cervical segments (C1-C2), (2) C4-5 segment, (3) levator scapulae near the insertion, and (4) the middle of supraspinatus/upper trapezius muscles. An investigator will palpate these four sites to determine the existence of tenderness and hypertonicity and tender points.

    Time frame: On the same day, this outcome measure will be collected twice: (1) Baseline, pre-intervention (2) Immediately after the intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Because some participants may not consent to broad data sharing.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2027, 7 months later.

Of 763 non-industry interventional studies with no phase under Neck Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 7 months is close to that.

Counting every sponsor, half of 772 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Nov 16, 2026
StartEst.
Jan 2, 2027
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939958
Lead sponsor
Sharon Wang-Price
Responsible party
Sharon Wang-Price (Professor, Texas Woman's University) — Sponsor-investigator
First posted
Nov 16, 2026
Start date
Jan 2, 2027 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Sharon Wang, PhD
Contact
swang@twu.edu
214-689-7715
Jace Brown, PhD
Contact
jbrown34@twu.edu
214-689-7716

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion